Generic Name and Formulations:
Dapagliflozin 5mg, 10mg; tabs.

Company:
Bristol-Myers Squibb and AstraZeneca

Indications for FARXIGA:
Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Limitation of use: not for treating type 1 diabetes or diabetic ketoacidosis.

Adult Dose for FARXIGA:
Take in the AM. Initially 5mg once daily; if tolerated and need additional glycemic control; may increase to 10mg once daily. Renal impairment: if eGFR <60mL/min/1.73m2: do not initiate. Discontinue if eGFR falls persistently <60mL/min/1.73m2.

Children's Dose for FARXIGA:
<18yrs: not established.

Pharmacological Class:
Sodium-glucose co-transporter 2 (SGLT2) inhibitor.

Contraindications:
Severe renal impairment, ESRD, or on dialysis.

Warnings/Precautions:
Correct volume depletion before starting therapy. Monitor for signs/symptoms of hypotension (esp. elderly, patients with renal impairment, or on diuretics). eva luate renal function prior to starting and monitor periodically thereafter. Increased risk of genital mycotic infections; monitor and treat if occurs. Monitor for increases in LDL-C; treat if occur. Active bladder cancer: do not use. Severe hepatic impairment. Elderly. Pregnancy (Cat. C). Nursing mothers: not recommended.

Interactions:
Concomitant insulin or insulin secretagogue: consider a lower dose of insulin/insulin secretagogue to reduce risk of hypoglycemia. Hypotension with concomitant loop diuretics.

Adverse Reactions:
Female genital mycotic infections, nasopharyngitis, UTIs, back pain, increased urination; volume depletion and renal impairment.

How Supplied:
Tabs—30, 90, 500